Stockreport

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomali...

OnKure Therapeutics, Inc. - Class A  (OKUR) 
PDF -- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Ka pan-mutant [Read more]